HEC211909
/ Sunshine Lake Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
Preclinical studies of HEC211909, an orally bioavailable, high potent pan-KRAS inhibitor
(AACR 2025)
- "HEC211909 is a highly potent and selective orally pan-KRAS(ON/OFF) inhibitor against KRAS G12D, KRAS G12C, KRAS G12V, KRAS Q61H, KRAS G13D mutations and also displays high selectivity over WT HRAS and NRAS, thus providing an expanded therapeutic index."
Preclinical • Oncology • Pancreatic Cancer • Solid Tumor • HRAS • KRAS • NRAS
1 to 1
Of
1
Go to page
1